Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children
- PMID: 18211614
- DOI: 10.1111/j.1365-2710.2008.00885.x
Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children
Abstract
Objective: To establish a regression equation to properly estimate the unbound serum concentration of valproic acid (VPA) from its total serum concentration; the relationship between total and unbound serum VPA concentrations was retrospectively characterized.
Methods: Data were obtained from the clinical examination records that were routinely archived during therapeutic drug monitoring. The screening encompassed 342 records of 108 paediatric patients whose total and unbound VPA concentrations had been determined. The relationship between total and unbound VPA concentrations was characterized according to the Langmuir equation by taking account of inter-individual variability with the nonmem program.
Results: The total VPA concentration (C(t)) in the screened patients ranged from 5.5 to 179.8 microg/mL, and the unbound VPA concentration (C(f)) increased in a non-linear manner as the total VPA concentration increased. Taking account of the effects of antiepileptics concurrently administered, the VPA dissociation constant (K(d)) and maximum binding site concentration (B(m)) were 7.8 +/- 0.7 and 130 +/- 4.5 microg/mL respectively, for the regression equation, C(t) = C(f) + B(m) x C(f)/(K(d) + C(f)). An alteration in the unbound concentration was seen in patients who were treated with the combination of VPA and ethosuximide and in those who received two additional antiepileptics.
Conclusions: A regression equation for estimation of the unbound VPA concentration, based on total VPA concentration collected during routine therapeutic drug monitoring was established. Use of two additional antiepileptics and ethosuximide treatment was considered as potential factors affecting unbound VPA concentration.
Similar articles
-
Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants.J Clin Pharm Ther. 2009 Aug;34(4):415-22. doi: 10.1111/j.1365-2710.2009.01022.x. J Clin Pharm Ther. 2009. PMID: 19583674
-
Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.Am J Ther. 2006 May-Jun;13(3):211-7. doi: 10.1097/01.mjt.0000155113.89092.58. Am J Ther. 2006. PMID: 16772762 Clinical Trial.
-
The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data.Epilepsy Res. 2006 Aug;70(2-3):153-60. doi: 10.1016/j.eplepsyres.2006.04.002. Epub 2006 May 30. Epilepsy Res. 2006. PMID: 16730950
-
Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.Clin Pharmacokinet. 1995 Oct;29(4):257-86. doi: 10.2165/00003088-199529040-00005. Clin Pharmacokinet. 1995. PMID: 8549027 Review.
-
[The use of intravenous valproate].Rev Neurol. 1999 Oct 16-31;29(8):744-53. Rev Neurol. 1999. PMID: 10560111 Review. Spanish.
Cited by
-
Apparent clearance of valproic acid in elderly epileptic patients: estimation of the confounding effect of albumin concentration.Ups J Med Sci. 2012 Mar;117(1):41-6. doi: 10.3109/03009734.2011.640412. Epub 2011 Dec 29. Ups J Med Sci. 2012. PMID: 22206465 Free PMC article.
-
A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.Eur J Clin Pharmacol. 2018 Jun;74(6):793-803. doi: 10.1007/s00228-018-2444-2. Epub 2018 Mar 21. Eur J Clin Pharmacol. 2018. PMID: 29564480
-
Modeling the protein binding non-linearity in population pharmacokinetic model of valproic acid in children with epilepsy: a systematic evaluation study.Front Pharmacol. 2023 Oct 6;14:1228641. doi: 10.3389/fphar.2023.1228641. eCollection 2023. Front Pharmacol. 2023. PMID: 37869748 Free PMC article.
-
Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death.J Cancer Res Clin Oncol. 2009 Jul;135(7):879-89. doi: 10.1007/s00432-008-0522-z. Epub 2008 Dec 9. J Cancer Res Clin Oncol. 2009. PMID: 19066961 Free PMC article.
-
A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.Clin Pharmacokinet. 2015 Mar;54(3):305-17. doi: 10.1007/s40262-014-0212-8. Clin Pharmacokinet. 2015. PMID: 25388986
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical